Multi-Stage Cannabinoid Formulation for Controlled Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cannabinoid compositions lack controlled bioavailability and delayed onset, leading to unpredictable therapeutic effects and potential adverse effects due to the challenges in pharmacokinetics of ingested cannabinoids, particularly in edible forms, where consumers may ingest excessive amounts before the effects are felt.
Innovation Solution
A formulation comprising two or more staged compositions with different release profiles, allowing for controlled initiation and management of cannabinoid and psychoactive compound effects, including immediate, controlled, or sustained release, using various dosage forms such as pills, patches, and lozenges, with bioavailability enhancers like N-acylated fatty amino acids and piperine to modify pharmacokinetic profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If edible cannabis extracts are consumed, then therapeutic effects are achieved, but delayed onset occurs leading to potential excessive consumption before effects are felt
Solution Approach 1:
The patent divides the single dose into multiple staged compositions with different release profiles. The formulation includes a first composition with immediate release and a second composition with delayed release, allowing the therapeutic effect to begin promptly while maintaining predictability about when additional effects will occur.
Solution Approach 2:
The patent incorporates bioavailability enhancers in the first composition that act immediately upon ingestion to accelerate the onset of therapeutic effects. This preliminary action ensures that consumers feel effects sooner, reducing the likelihood of excessive consumption before expecting any effect.
2Ease of operation
If single-dose cannabinoid compositions are used, then simplicity of administration is maintained, but controlled bioavailability is not achieved
Solution Approach 1:
The patent merges multiple compositions with different release profiles into a single dosage form. The formulation combines an immediate-release composition with a delayed-release composition, allowing consumers to take only one action (ingest the single dose) while achieving controlled, multi-stage bioavailability.
Solution Approach 2:
The patent structures the formulation so that the delayed-release composition is contained within or integrated with the immediate-release composition. The single dosage form encapsulates multiple staged compositions that release at different times, maintaining ease of administration while achieving precise control over bioavailability timing.
3Ease of manufacture
If conventional cannabinoid formulations are used, then manufacturing simplicity is maintained, but multi-stage bioavailability is not achieved
Solution Approach 1:
The patent segments the cannabinoid formulation into distinct first and second compositions with different release characteristics. The first composition provides immediate bioavailability while the second composition provides prolonged, delayed release, achieving extended duration of action through segmented formulation rather than complex single-phase formulations.
Solution Approach 2:
The patent implements periodic release of cannabinoid compositions at different time intervals. The formulation is designed to release the first composition immediately and then release the second composition after a delayed period, creating a periodic action pattern that extends the overall duration of therapeutic effect while maintaining manufacturing feasibility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The multi-stage formulation ensures controlled and prolonged bioavailability of cannabinoids, allowing for tailored therapeutic effects and reduced risk of adverse effects by managing the release of active agents over time, enhancing the safety and efficacy of cannabinoid administration.
Implementation Method 1
one or more staged composition comprises one or more bioavailability enhancers
Implementation Method 2
with bioavailability enhancers like N-acylated fatty amino acids and piperine to modify pharmacokinetic profiles
Implementation Method 3
A formulation comprising two or more staged compositions with different release profiles, allowing for controlled initiation and management of cannabinoid and psychoactive compound effects
Implementation Method 4
including immediate, controlled, or sustained release
Data Source
AI summary
A method for dispensing opioids using a dispensing container in an anti-addiction pain-modulating regimen includes generating a dosage scheme for dispensing an opioid compound using the dispensing container including a controller programmable according to the dosage scheme and locked compartments storing the opioid compound. The dosage scheme includes a first dosage scheme for an opioid compound and a first dosage scheme for a cannabinoid compound to be administered to the patient concurrently over a period of time. The method includes sending the dosage scheme for operating the dispensing container. The controller stores one or more authentication programs and is programmed to authenticate the patient using the one or more authentication programs, and in response to authenticating the patient, unlock one or more of the compartments to allow the patient to access to a dosage of the opioid compound held in the one or more compartments according to the dosage scheme.